Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

1.

Usefulness of insulin detemir in Japanese children with type 1 diabetes.

Jinno K, Urakami T, Horikawa R, Kawamura T, Kikuchi N, Kikuchi T, Kizu R, Kosaka K, Mizuno H, Mochizuki T, Nishii A, Ohki Y, Soneda S, Sugihara S, Tatematsu T, Amemiya S; Japanese Study Group of Insulin Therapy for Childhood and Adolescent Diabetes.

Pediatr Int. 2012 Dec;54(6):773-9. doi: 10.1111/j.1442-200X.2012.03687.x. Epub 2012 Sep 17.

PMID:
22726205
[PubMed - indexed for MEDLINE]
2.

Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.

Nimri R, Lebenthal Y, Shalitin S, Benzaquen H, Demol S, Phillip M.

Pediatr Diabetes. 2013 May;14(3):196-202. doi: 10.1111/pedi.12012. Epub 2013 Jan 4.

PMID:
23289822
[PubMed - indexed for MEDLINE]
4.

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.

Johansen OE, Vanberg PJ, Kilhovd BK, Jørgensen AP.

Vasc Health Risk Manag. 2009;5(1):121-8. Epub 2009 Apr 8.

PMID:
19436668
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

A bridge to insulin pump therapy: twice-daily regimen with NPH and detemir insulins during initial treatment of youth with type 1 diabetes mellitus.

Cengiz E, Sherr JL, Erkin-Cakmak A, Weinzimer SA, Burke EN, Sikes KA, Urban AD, Tamborlane WV.

Endocr Pract. 2011 Nov-Dec;17(6):862-6. doi: 10.4158/EP11031.OR.

PMID:
21550949
[PubMed - indexed for MEDLINE]
6.

Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study.

Renard E, Dubois-Laforgue D, Guerci B; Variability Study Group.

Diabetes Technol Ther. 2011 Dec;13(12):1213-8. doi: 10.1089/dia.2011.0063. Epub 2011 Aug 2.

PMID:
21810024
[PubMed - indexed for MEDLINE]
7.

Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.

Kabadi UM.

Clin Drug Investig. 2008;28(11):697-701.

PMID:
18840012
[PubMed - indexed for MEDLINE]
8.

An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.

Fujii H, Watanabe Y, Ueki A, Ohno A, Kato M, Kondo K, Takamura H, Takesue M, Nishimura H, Matsuda D, Miyakawa T.

Int J Clin Pract. 2010 Oct;64(11):1512-9. doi: 10.1111/j.1742-1241.2010.02391.x.

PMID:
20678116
[PubMed - indexed for MEDLINE]
9.

Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes.

Braun D, Konrad D, Lang-Muritano M, Schoenle E.

Pediatr Diabetes. 2008 Aug;9(4 Pt 2):382-7. doi: 10.1111/j.1399-5448.2008.00371.x. Epub 2008 Mar 5.

PMID:
18331413
[PubMed - indexed for MEDLINE]
10.

Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.

Kurtoglu S, Atabek ME, Dizdarer C, Pirgon O, Isguven P, Emek S; PREDICTIVE Turkey Study Group.

Pediatr Diabetes. 2009 Sep;10(6):401-7. doi: 10.1111/j.1399-5448.2008.00497.x. Epub 2009 Feb 11.

PMID:
19220776
[PubMed - indexed for MEDLINE]
11.

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.

Hollander P, Cooper J, Bregnhøj J, Pedersen CB.

Clin Ther. 2008 Nov;30(11):1976-87. doi: 10.1016/j.clinthera.2008.11.001.

PMID:
19108786
[PubMed - indexed for MEDLINE]
13.

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.

Clin Ther. 2004 May;26(5):724-36.

PMID:
15220016
[PubMed - indexed for MEDLINE]
14.

Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.

Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V.

Diabet Med. 2013 Feb;30(2):216-25. doi: 10.1111/dme.12041.

PMID:
23094597
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy.

Dündar BN, Dündar N, Eren E.

J Clin Res Pediatr Endocrinol. 2009;1(4):181-7. doi: 10.4008/jcrpe.v1i4.56. Epub 2009 May 4.

PMID:
21274293
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Insulin detemir: a review of its use in the management of diabetes mellitus.

Keating GM.

Drugs. 2012 Dec 3;72(17):2255-87. doi: 10.2165/11470200-000000000-00000. Review.

PMID:
23110609
[PubMed - indexed for MEDLINE]
17.

A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.

Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA.

Pediatrics. 2008 Mar;121(3):e466-72. doi: 10.1542/peds.2007-1679. Epub 2008 Feb 25.

PMID:
18299307
[PubMed - indexed for MEDLINE]
Free Article
18.

Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.

Chacra AR, Kipnes M, Ilag LL, Sarwat S, Giaconia J, Chan J; COMPLETE T1D investigators.

Diabet Med. 2010 May;27(5):563-9. doi: 10.1111/j.1464-5491.2010.02986.x.

PMID:
20536953
[PubMed - indexed for MEDLINE]
19.

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.

Standl E, Lang H, Roberts A.

Diabetes Technol Ther. 2004 Oct;6(5):579-88.

PMID:
15628811
[PubMed - indexed for MEDLINE]
20.

Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).

Le Floch JP, Lévy M, Mosnier-Pudar H, Nobels F, Laroche S, Gonbert S, Eschwege E, Fontaine P; Assessment of Detemir Administration in Progressive Treat-to-Target Trial (ADAPT) Study Group.

Diabetes Care. 2009 Jan;32(1):32-7. doi: 10.2337/dc08-0332. Epub 2008 Oct 22.

PMID:
18945928
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk